Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9HBY5)

• Drug Name: 6-Deoxy-Alpha-D-Glucose Drug Info
• Synonyms: alpha-D-Quinovopyranose; 6-deoxy-alpha-D-glucopyranose; UNII-68BDH91OBS; 68BDH91OBS; Isorhodeose; Isorhamnose; D-Epifucose; D-Glucomethylose; D-Chinovose; 6-DEOXY-ALPHA-D-GLUCOSE; 551-63-3; alpha-D-quinovose; 3h-6-deoxyglucose; alpha-D-Quinovose pyranose; AC1L9B8Y; SCHEMBL79180; CHEBI:42606; alpha-D-Glucopyranose, 6-deoxy-; ZINC2042980; DB03773; C08352; (2S,3R,4S,5S,6R)-6-methyloxane-2,3,4,5-tetrol

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 6713579
  CAS Number: CAS 71116-61-5
  TTD Drug ID: DM9HBY5

Molecule-Related Drug Atlas

Drug(s) Targeting Alpha-glucosidase (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[2]
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[3]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[4]
Anamorelin	DM6HXTS	Carbohydrate metabolism disorder	5C51.Z	Phase 3	[5]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[6]
AAV2/8-LSPhGAA	DMIX5HF	Pompe disease	5C51.3	Phase 1	[7]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[1]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[1]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[1]
POP-1	DMVTKCX	Solid tumour/cancer	2A00-2F9Z	Investigative	[8]

Drug(s) Targeting Pancreatic alpha-amylase (AMY2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pancrecarb	DMOML9Q	Pancreatic malfunction	DC30-DC3Z	NDA filed	[9]
Liprotamase	DMNF4UH	Cystic fibrosis	CA25	Phase 3	[10]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[1]
Pyroglutamic Acid	DMROZUA	Discovery agent	N.A.	Investigative	[1]
Acanthus ilicifolius Linn	DMZDFRI	Discovery agent	N.A.	Investigative	[11]
Acarbose Derived Hexasaccharide	DMS9COH	Discovery agent	N.A.	Investigative	[1]
Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam	DMMY542	Discovery agent	N.A.	Investigative	[6]
Hydroxycitric acid	DMY0A9E	Discovery agent	N.A.	Investigative	[12]
Alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen	DM4IXUQ	Discovery agent	N.A.	Investigative	[13]
Alpha-acarviosinyl-(1-->7)-3-alpha-D-glucopyranosylpropen	DMHV14R	Discovery agent	N.A.	Investigative	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alpha-glucosidase (GLA)	TTHCF4J	LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN	Inhibitor	[1]
Pancreatic alpha-amylase (AMY2A)	TTCGSZ4	AMYP_HUMAN	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Cipaglucosidase Alfa: First Approval. Drugs. 2023 Jun;83(8):739-745.
• [3] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761204
• [4] Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
• [5] Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
• [6] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [7] ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health.
• [8] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
• [9] Clinical pipeline report, company report or official report of Digestive Care.
• [10] Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
• [11] Four acarviosin-containing oligosaccharides identified from Streptomyces coelicoflavus ZG0656 are potent inhibitors of alpha-amylase. Carbohydr Res. 2008 Apr 7;343(5):882-92.
• [12] Chemistry, physiological properties, and microbial production of hydroxycitric acid. Appl Microbiol Biotechnol. 2007 Jul;75(5):977-82.
• [13] Enzymatic synthesis of a selective inhibitor for alpha-glucosidases: alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen. J Agric Food Chem. 2008 Jul 9;56(13):5324-30.